Centro Privado de RMI Río Cuarto S.A. II ( Site 0310)

Río Cuarto, Córdoba Province X5800ALB

1 studies enrolling now · 2 studies all time

What they study most

Non-small Cell Lung Cancer (NSCLC)

Studies at this site

• Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007) — Recruiting now
• Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) — Running, not enrolling